Levine, Arnold J. http://orcid.org/0000-0002-1871-6387
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (PO1 CA087497)
Article History
Received: 10 May 2021
Accepted: 2 August 2021
First Online: 13 August 2021
Competing interests
: AJL is a founder, board member and shareholder in PMV Pharmaceuticals that produce small molecule reactivators of p53 mutant proteins. He is on the board and holds stock options in Meira GTX (retinal gene therapy) and Genecentric (RNA diagnostics) and receives fees for advice to Pharmabody (monoclonal antibodies). He is a member of the SAB of InterVenn Biosciences, and Janssen Pharmaceuticals.